Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Conditions: Chronic Spontaneous Urticaria Interventions: Biological: LP-003; Biological: Placebo; Biological: Omalizumab Sponsors: Longbio Pharma Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials